Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

Eli Lilly (LLY) has partnered with the government of the United Kingdom to see if its blockbuster weight loss drug could help ...

The one problem Lilly has faced is meeting the soaring demand for these products. In fact, they are so popular that the U.S.

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

The FDA has agreed in court to allow compounding pharmacies to continue producing compounded versions of LLY's tirzepatide ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Compounding pharmacies can make tirzepatide againIn a reversal, the Food and Drug Administration ...

All the evidence gathered from the five-year trial will be used to demonstrate the long-term effect of weight loss medication ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...